RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Conditions: Systemic Sclerosis; Scleroderma Interventions: Biological: CABA-201 Sponsors: Cabaletta Bio Not yet recruiting

Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials